ASDM licences synthetic bone substitute with University of Sydney

THE ROADHOUSE PHARMACY: Orthopaedic devices manufacturer, Advanced Surgical Design and Manufacture Limited (ASDM) (ASX: AMT) has executed a global Licence Agreement with The University of Sydney relating to a composite biocompatible ceramic material known as Sr-HT-Gahnite.

ASDM is to facilitate the commercialisation of veterinary and orthopaedic solutions based on the composite biocompatible ceramic material developed by the University.

“Existing synthetic bone substitute materials are unable to be used to treat bone loss in load bearing applications,” ASDM CEO Tom Milicevic said in the company’s announcement to the Australian Securities Exchange.

“Consequently, bone autograft and allografts and/or metal implants are required.

“In preliminary studies, Sr-HT-Gahnite has duplicated the mechanical strength, elasticity and bioactivity of bone.

“Importantly, it is 100 times mechanically stronger than synthetic bone substitute materials in clinical use.”

Milicevic described the project as an exciting one for ASDM in that it fits the company’s strategy of developing a portfolio of products in orthopaedics.
 
“This material is a novel breakthrough technology with huge global potential,” he continued.

“According to the 2010 GlobalData report, the Bone Graft market was valued at US$1.9 billion and is forecast to grow by a CAGR of 8.3 per cent more than doubling the market by 2020.”
 
The University of Sydney said it was pleased to be working closely with ASDM.

“We are very excited by the opportunity to work so closely with a leading Australian orthopaedic device manufacturer,” University of Sydney commercial development and industry partnerships director Andrew Tindell said.

“This materials technology represents the culmination of 22 years of world leading research and it is always rewarding when the University sees the outputs of its work taken up by industry, developing products and bringing them to the market.”

Website: www.asdm.com.au

Antisense releases Toxicology Study findings

THE ROADHOUSE PHARMACY: Antisense Therapeutics (ASX: ANP) released results from a chronic toxicity study in monkeys, which it says indicate ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose).

The company believes the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level.

Based on histologic findings in common with a previous monkey study at doses exceeding 1.5mg/kg/dose, the company indicated it is continuing to evaluate the chronic monkey data with regard to potential human relevance, and safety biomarkers that may be useful in future clinical studies.

Antisense explained exposures achieved in this study are regarded as potentially clinically relevant based on the efficacy outcomes from the previously conducted Phase IIa trial of ATL1102 in MS patients.

Pending receipt and final data evaluation from the current study, as well as review of all the preclinical and clinical data obtained, Antisense is planning future regulatory agency discussions regarding further development of ATL1102 and the dosing regimen for a future Phase IIb trial in MS patients.

The company anticipates final review of the data by June this-year and follow-up discussions with the US Food and Drug Administration (FDA) at a pre-IND meeting during the 3rd quarter 2014.

“The results of this most recent toxicology study and the human data to date are encouraging and re-ignite our hopes for this project,” Antisense Therapeutics CEO and managing director Mark Diamond said in the company’s announcement to the Australian Securities Exchange.

“We are continuing to generate new data on ATL1102 which we believe will support positive interactions with the FDA in relation to our plans for a future Phase IIb trial in MS patients.

“We look forward to confirming our plans for the further clinical development of ATL1102 with the FDA in the coming months.”

Website: www.antisense.com.au

Nanosonics signs strategic partnership

THE ROADHOUSE PHARMACY: Nanosonics Limited (ASX: NAN) has entered into a strategic partnership with Miele Professional for the distribution of trophon®EPR in Germany.

Miele Professional is a world leading authority and provider of medical disinfection and sterilisation equipment and specialises in the development of washer-disinfectors for hospitals and surgeries.

“This strategic partnership brings together two world leading authorities in the field of medical equipment disinfection” Nanosonics president/CEO Michael Kavanagh said in the company’s announcement to the Australian Securities Exchange.

“Partnering with Miele provides a great opportunity to establish the trophon®EPR as the new standard of care for the high level disinfection of ultrasound probes in the important German market.

“Working with such a globally recognised brand and leader in the field of medical disinfection and sterilisation is testimony to the innovation that the trophon®EPR brings.”

Miele Professional said it considers the trophon®EPR to be a good example of innovation that not only strategically fits well with the company’s disinfection and sterilisation portfolio of products but also with the credo by which it operates of ‘Forever Better’.

“It is clear the German Market requires a new solution for the effective disinfection of ultrasound probes and trophon®EPR meets the necessary criteria to become established over time as the new standard of care,” Miele Professional head Andreas Barduna said.

Nanosonics explained that currently either wipes or immersion in toxic chemistry such as gluteraldehyde are the primary methods of ultrasound probe disinfection in Germany.

The company said recommendations of the commission for hospital hygiene and infection prevention at the Robert Koch Institute (RKI), indicate a preference for using automated reprocessing systems.

However, up until now such automated systems for the disinfection of ultrasound probes did not exist.

Miele will conduct a National launch of trophon®EPR at the DGKH-congress (German Society of Hospital Hygiene) in Berlin on 30 March then commence broad market awareness and education programs for the product across Germany.

Email: info@nanosonics.com.au

Website: www.nanosonics.com.au

Regeneus osteoarthritis treatment shows continued improvement

THE PHARMACY: Regenerative medicine company, Regeneus (ASX: RGS) announced further results from its ethics approved joint registry used to track the safety and effectiveness of the company’s innovative cell therapy, HiQCell®, in the treatment of osteoarthritis.

The interim report of 305 patients, as at 23 January 2014, has found that:

Patients reported continued improvements at 12 months post-treatment;

The small number of patients (7) within the Registry that had reached 24 months post-treatment also show continued improvements;

Patients reported improvements in pain, function, sleep quality and reduced usage of pain medications;

73 per cent of patients treated experienced a (greater than 30 per cent) reduction in pain with an average reduction of 79 per cent across all age groups and osteoarthritis grades; and

HiQCell is a safe therapy and well tolerated by patients.

 

Percentage of pain level for responders experiencing more than 30
per cent pain reduction from baseline. Source: Company announcement

 

Regeneus explained the HiQCell Joint Registry as being the first of its kind in the long-term follow-up of patients undergoing stem cell therapy using the patient’s own fat-derived stem cells.

Patients in the Registry will continue to be followed for up to five years with analyses updated regularly.

Within the registry a patient is classified as a responder if they report a greater than 30 per cent reduction in pain.

At 12 months post treatment 56 of 77 patients were responders and at 24 months post treatment
6 of 7 patients were responders.

“The Joint Registry is an important part of the company’s commitment to quality,” Regeneus CEO, professor Graham Vesey said in the company’s announcement to the Australian Securities Exchange.

“Recording patient outcomes over the long term is an example of our responsible approach towards furthering the medical community’s understanding of this new therapeutic field.

“It is exciting that we have registry data available for 12 months and beyond post-treatment for patients.

“We anticipate that it will also help us to build a case for permitting medical reimbursement to patients.”

The Joint Registry is a voluntary observational registry and all patients treated with HiQCell are eligible for inclusion.

Patients are tracked from a pre-treatment baseline, at two weeks, at six months and then annually.

Three hundred and five patients had consented to be included in the registry as of 23 January 2014, representing 77 per cent of all patients treated.

Email: investors@regeneus.com.au

Website: www.regeneus.com.au

Patrys completes successful clinical trial

THE PHARMACY: Patrys Limited (ASX: PAB) has received final results from a Phase I/IIa, open-label study of PAT-SM6 in patients with refractory or relapsed multiple myeloma (MM).

Patrys explained the trial was conducted in 12 patients (10 male and 2 female, median age 71 years) with refractory or relapsed MM.

The primary endpoint of the study was safety and tolerability.

The company said at all dose levels tested, PAT-SM6 was well tolerated with no serious adverse events (SAEs) or dose limiting toxicities being reported. A maximal tolerated dose (MTD) was not reached.

Secondary endpoints were designed to measure efficacy as determined by a series of well-established laboratory assays.
 
Overall, 4/12 patients (33 per cent) treated with PAT-SM6 showed evidence of stable disease (SD) according to the International Myeloma Working Group (IMWG) criteria.

Patrys highlighted that patients treated with PAT-SM6 had a mean time to next therapy of 51 days which, it said is considered clinically significant.

Patients who had received prior treatment with proteasome inhibitors responded much better to PAT-SM6 treatment than patients who had been previously treated with IMIDs or other chemotherapeutics.

The company was excited by this saying it indicates PAT-SM6 may act synergistically with proteasome inhibitors (such as Carfilzomib) to induce better clinical responses.

This will be tested in Patrys’ next clinical trial in which PAT-SM6 will be used in combination with Amgen’s Carfilzomib.

“The trial results are especially exciting because they reflect single-agent activity in a difficult-to-treat population Patrys Limited CEO Dr. Marie Roskrow said in the company’s announcement to the Australian Securities Exchange.

“Due to very high rates of relapse, the combination of multiple agents is increasingly becoming a therapy of choice for patients with MM.

“Therefore, the results obtained in this trial strongly support further evaluation of PAT-SM6 in combination with Carfilzomib which is the basis of our planned Amgen sponsored clinical trial.”

Email: info@patrys.com

Website: www.patrys.com

This Week in The Roadhouse Pharmacy

THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.

Patrys completes successful clinical trial

Patrys Limited (ASX: PAB) has received final results from a Phase I/IIa, open-label study of PAT-SM6 in patients with refractory or relapsed multiple myeloma (MM). READ MORE…

Regeneus osteoarthritis treatment shows continued improvement

Regenerative medicine company, Regeneus (ASX: RGS) announced further results from its ethics approved joint registry used to track the safety and effectiveness of the company’s innovative cell therapy, HiQCell®, in the treatment of osteoarthritis. READ MORE…

Bone Medical ties up BN006 research collaboration

Bone Medical Ltd (ASX: BNE) has entered into a research agreement with William Harvey Research Limited (WHRL), to further study the company’s anti-inflammatory molecule for rheumatoid arthritis (RA), BN006, and support its progress towards clinical studies in man. READ MORE…

Imugene allowed Israel patent for cancer vaccine

Australian biopharmaceutical company Imugene Limited (ASX: IMU) has been issued an Intention to Grant notice from the Israeli Patent Office for the company’s proprietary cancer vaccine HER-Vaxx (Patent no. IL 194162, 2027expiry). READ MORE…

Patrys advances PAT-LM1 to clinical development

Clinical stage biotechnology company Patrys Limited (ASX: PAB) has released an update on the development program for the company’s anti-cancer product, PAT-LM1. READ MORE…

Raising funds across the Boards

THE FUND RAISER: There’s been some happy explorers boosting their coffers this week.

$2.1 million to accelerate El Roble

Mining Group (ASX: MNE) has received commitments to raise up to approximately $2.1 million by way of a placement of up to 75 million fully paid ordinary shares at an issue price of 2.8 cents per share.

It is expected the new shares will be issued on or around 31 March 2014.

The funds raised from the Placement will be applied towards further exploration and to accelerate progress towards development at the El Roble copper project in Chile.

“This injection of capital ensures the company is well positioned to execute its strategy of entering into low cost underground production very quickly,” Mining Group managing director Zeff Reeves said.

“We have identified a number of additional new areas where we see potential to support a small, high grade, underground operation and these funds will assist in accelerating our work programs to assess these new areas and move quickly towards mining if results are positive.

“To date our work has demonstrated the potential of El Roble to provide a very low cost, small scale, high-grade copper production and the next few months are looking to be very exciting for the company.”

Raises $2 million for Big Springs project

Anova Metals (ASX: AWV) is seeking to place up to 50 million new ordinary shares at an issue price of 4 cents per share to raise up to $2 million.

To date firm commitments have been received for $1.52 million, with the company anticipating the balance of funds to be committed over the next week.

The new shares will be placed with institutional and sophisticated investors.

The funds raised will allow the company to continue to advance its 100 per cent-owned Big Springs project towards production.

$1.7 million Placement

Talga Resources (ASX: TLG) has received $1.7million in funds as part of a placement to professional and sophisticated investors via the issue of 20 million ordinary shares at 8.5 cents per ordinary share.

“The company is now fully funded to complete metallurgical and other tests that will result in a dual graphite/graphene preliminary economic study of the Nunasvaara graphite project in northern Sweden,” Talga Resources managing director Mark Thompson said.

“The Placement attracted encouraging support from major shareholders including Yandal Investments Pty Ltd, a company controlled by prominent prospector Mark Creasy plus new shareholders with significant interest in the graphite space.”

$10 million in over-subscribed Share placement

Gold Road Resources (ASX: GOR) has received firm commitments to raise $10 million via a placement of shares.

The over‐subscribed Placement to existing and new institutional and sophisticated investors was completed at 17.5 cents a share.

The Company is now well-funded to continue its exploration programs and technical studies.

The funds raised, together with existing cash reserves, will allow the company to pursue an aggressive exploration strategy and studies at its Gruyere prospect, as well as to undertake additional regional exploration along the Dorothy Hills Trend and other high‐priority Gold Camp Targets.

$1.6 million to fund major gold exploration push

Genesis Minerals (ASX: GMD) is raising $1.33 million by way of an ordinary share placement to sophisticated investors and a further US$250,000 placement to Teck.

This capital raising will allow Genesis to complete a Phase 2 drill program at the Las Opeñas precious and base-metal epithermal project located in the pre-cordillera of San Juan Province, Argentina targeting the large, well mineralised breccia system discovered by Genesis drilling during 2012.

In Western Australia Genesis will commence a systematic test of a series of high-grade vein targets and surface gold anomalies that have been outlined to date at the 7km by 7km Beaker prospect at Genesis’ 100 per cent-owned Viking project near the historical gold centre of Norseman.

“Teck’s decision to invest in Genesis is positive and validates our belief in the Las Opeñas project and its potential to deliver a significant deposit,” Genesis Minerals managing director Michael Fowler said.

“The proceeds of the Placements will enable the company to complete a strong exploration push over the coming months with a significant drill program to test the potential scale and tenor of the gold-base metal mineralisation at the large Las Opeñas breccia system and a cost effective program at our local Viking project to rapidly drill-test a series of high-grade gold targets.”

What the Brokers Say

WHAT THE BROKERS SAY: Interesting news and views from across the Resource Analyst universe.

www.breakawayresearch.com

Auroch Minerals (ASX: AOU)

Auroch Minerals’ (ASX: AOU) Manica gold project hosts a significant JORC Resource of 48.9 million tonnes at 1.79 grams per tonne gold for 2.82 million ounces.

The company now has put in place a clear three stage strategy which envisages mining the non-refractory component of the ore body first, providing the framework and cash flow necessary to advance the larger and potentially more lucrative refractory project.

A DFS is underway with the company targeting first production as early as Q4 2015.

The Manica project, located in Mozambique, hosts its current JORC Resource at four nearby deposits.

Approximately 90 per cent of the resource is hosted within sulphide ore zones (refractory) while the remaining (approx.) 10 per cent of the resource (approx. 258,000 ounces) is hosted within free milling, transitional or oxide (non-refractory) ore zones.

It is these non-refractory ore zones which provide a near term path to production.

Auroch recently updated the 2013 Scoping Study to reflect a new 3 Stage strategy which envisages initial mining and processing of the non-refractory ore zones at various satellite deposits, followed by an expansion to process the larger and potentially more lucrative refractory ore zones.

Manica is located on a 25 year mining lease and already well serviced by local infrastructure such as telecommunications, local airport, roads, rail, power and water, minimising the upfront capital costs and time line to production.

Auroch is well advanced with metallurgical test work and infill drill campaigns required for the DFS, which is being supported by a ZAR 8M (approx. A$870,000) grant from the Department of Trade and Industry of South Africa.

Importantly, this grant now opens up the potential to receive further funding on a project level from other South African based financiers.

Website: www.breakawayresearch.com

PLD Corporation (ASX: PLD)

PLD Corporation is an early stage nickel-copper exploration company with exposure to a highly prospective project located in the Albany-Fraser belt of Western Australia.

Shallow RAB drilling at two targets (of 36 identified) demonstrate a geological setting considered directly analogous to the Nova-Bollinger discovery, also located within the Albany-Fraser Belt.

Upcoming drilling provides opportunity for positive news flow and a substantial valuation re-rating.

PLD Corporation (ASX: PLD) has entered into binding option agreements for an exclusive 12 month period to acquire a 90 per cent interest in the Rocky Gully nickel-copper project (comprising 3 tenements), located in the southern corner of the Albany-Fraser Belt from ASX-listed Heron Resources.

A further option agreement was signed with a private group for a 100 per cent interest in a contiguous Exploration Licence Application (with both option agreements now covering four licences).

PLD has already made non-refundable payments totalling $80,000 to secure the option agreements and, should the company elect to exercise, it will pay a further $280,000 (or 28.75 million PLD shares issued at 0.8 cents) to Heron and 5 million shares to the private group (at 1 cent).

Heron will retain a 10 per cent interest in 3 licences and a Net Smelter Royalty (NSR) of 1.5 per cent.

The Rocky Gully project hosts 10 ‘priority’ nickel-copper targets, however, the two of most significance are the ‘M19’ and ‘M20’ prospects.

Historical shallow RAB drilling intersected strongly anomalous nickel-copper zones within lateritic horizons in a setting that is considered directly analogous to that of Sirius’s Nova-Bollinger discovery.

An upcoming RC drill campaign has been designed to test these highly prospective nickel-copper targets, with first results expected before the end of June 2014.

PLD has a management team with extensive experience in exploration, development and mining, providing confidence of stringent exploration.

With an EV of $1.9 million, PLD is highly leveraged to any positive news flow.

Disclaimer: The above is intended as a guide only. The Roadhouse accepts no responsibility for investments made from this advice, successful or otherwise.

The views, opinions or recommendations of this article do not in any way reflect the views, opinions, recommendations, of The Resources Roadhouse.

The Roadhouse makes no representation or warranty with respect to the accuracy, completeness or currency of the content. The content is for educational purposes only and does not constitute financial advice. Independent advice should be obtained from an Australian financial services licensee before making investment decisions.

Mines and Money Hong Kong

THE CONFERENCE CALLER: Mining, so the experts say, is a cyclical industry with the current cycle not pedalling along at quite the same clip as when the boom was in full swing.

Although it has, to my knowledge, never been proved scientifically, it seems that when you place a large number of people from the one industry group in a large room, there is a good chance not all will be happy about being there.

So it seems with mining industry conferences of late.

A couple of short years ago these events were full to the brim with booths, manned by a number of company personnel along for the junket, who were kept busy repeating the details of the latest copper, gold, iron ore, whatever project to hordes of investors ranging from retail mums and dads  to sophisticated institutional types.

Managing directors were happy, event organizers were happy, everybody was happy, especially local restaurateurs, bar owners and the top-range hotel chains.

One aspect of this week’s Mines and Money Conference in Hong Kong was the number of companies in attendance who really didn’t want to be there.

 

A popular line being delivered to The Roadhouse was, “we’re only here because we signed up at the end of last years’ conference.”

Others bemoaned, what they considered to be, “not much traffic”, of visitors to their booths.

That is not to say there weren’t any happy campers, because there were, many in fact, their ranks bolstered by the companies who currently have good stories to tell – ones that investors of all persuasion are eager to learn more about.

There’s no secret the junior exploration sector is currently ‘doing it tough’.

Its cause hasn’t been helped by the new JORC Code 2012 regulations that prevent companies from declaring what potential their projects may hold using an Inferred Resource.

Instead they are forced to spend more money on further drilling to bring it up to the Indicated category, presenting them with a Catch-22 scenario of how do they encouraging investors to participate in a fund raising to continue drilling a project they’re not fully-able to tell the market about?

The industry will be watching the upcoming budget of recently-minted Federal Treasurer, Joe Hockey closely to see whether or not he follows the example set by the Rudd government with its first budget and ignores pre-election pledges to introduce tax concessions for exploration.

Manning the Mines and Money booths were …

Talga Resources (ASX: TLG) managing director was showing everybody who stopped by his booth an example of just how good the company considers the ore from the Nunasvaara graphite deposit is.

The Nunasvaara graphite deposit is within the company’s Vittangi project in Sweden.

Talga claims the deposit to be the world’s highest grade JORC/N143-101 resource at 7.6 million tonnes at 24.4 per cent graphite.

At the company’s booth Thompson had rigged up a torch globe and a couple of batteries to a drill core sample of ore from the project.

His intention was to demonstrate how the ore from the Nunasvaara graphite deposit conducts electricity, something graphite ore, generally is not capable of doing.

Thompson was able to get the point of his demonstration over to some delegates while others seemed somewhat baffled by the exercise.

Somebody must have seen the benefit of his endeavours, however, as the company’s share prices jumped 41.38 per cent the day following his speaking slot with over 3 million shares changing hands.

We also stopped by the booth of Middle Island Resources (ASX: MDI) and caught up with the company’s managing director Rick Yeates.

The company is looking to acquire a majority interest in the Samira Hill gold mine and mill in Niger.

Middle Island currently has a 70 to 100 per cent interest in seven permits surrounding Samira Hill.

In December 2013 SOPAMIN (Niger Government mining agency) picked up the balance of the Samira Hill project from SEMAFO Inc.

Middle Island has opened up discussions with SOPAMIN and the Government with the intention of acquiring a majority stake in the project.

Samira Hill consists of a two million tonnes per annum CIL processing facility with access to grid power and a 6 megawatt power station.

From remaining reserves at the project Middle Island has modelled 2 to 3 years production at around 50,000 ounces per annum with a potential mine life of over eight years, if Inferred Resources are successfully converted.

Doing the rounds of the exhibition space with a spring in his step was Stavely Minerals (Proposed ASX Code: SVY) managing director Chris Cairns.

The smile on his dial was impossible to erase after the company announced the opening of its $6 million Initial Public Offering.

Stavely management is made up of the team of former gold mining company Integra Mining, featuring Cairns, non-executive director Peter Ironside, and technical director Jennifer Murphy.

Integra was a 100,000 ounces per annum gold producer, before being taken over by Silver Lake Resources on the eve of the Diggers and Dealers Conference in Kalgoorlie in 2012.

The company’s key assets include a suite of prospective porphyry copper, copper-gold and gold assets in Western Victoria.

Funds raised through the Stavely Minerals IPO will be used to progress exploration at two key copper deposits in western Victoria, the Ararat and Stavely projects, which were acquired from ASX-listed BCD Resources (ASX: BCD).

The two projects cover an area of 193 square kilometres in Western Victoria, and include JORC resources containing over 130,000 tonnes of copper and 18,000 ounces of gold.

Since the acquisition, Stavely has applied for additional exploration tenure in the region and now holds around 776sqkm of exploration tenements and applications.

These areas are prospective for volcanogenic massive sulphide (VMS) copper-gold, porphyry copper-gold and Stawell-style gold deposits.

Red tape ‘Repeal Day’

IN THE LOBBY: On the eve of the APPEA conference in Perth next week The Minerals Council of Australia and The Australian Petroleum Production & Exploration Association released a joint statement on the Federal Government’s Red tape ‘Repeal Day’.

The groups banded together as Australia’s resources sector to welcome the Federal Government’s efforts to curb what they identified as the high costs and inefficiencies associated with project development in Australia.

The MCA and APPEA said they and hoped the ‘Repeal Day’ legislation marks the start of a concerted effort to boost the sector’s global competitiveness.

“Already the Government has committed to delivering a ‘one stop shop’ for environmental approvals to improve Australia’s investment climate,” the announcement said.

“This will simplify the approvals process for businesses and investors while maintaining high environmental standards.”

The two groups declared they considered the measures already announced by the Government to date to be a solid start, saying they are sorely needed if the resource sector is to secure further investment amid growing global competition.

The industry, they claimed, has long argued that duplicative requirements both within and between jurisdictions can be streamlined while maintaining the highest of environmental standards.

MCA and APPEA said the Repeal Day marks the start of an ongoing reform process and the industry looks forward to further repeal initiatives.

To support their case they cited the red tape associated with the ‘water trigger’, which was introduced into the Environment Protection and Biodiversity Conservation Act 1999 (EPBC Act) prior to the last federal election – a piece of legislation they claim addresses a political objective rather than an environmental one.

“The law was developed without any regulatory impact statement,” the announcement said.

“It covers only the activities of resources companies while ignoring the vast majority of water users.

“It duplicates existing state laws, requires new resource sector project proponents to pass both federal and state environmental assessments, while adding unnecessary layers to approvals processes that can increase project costs by millions of dollars.”

The joint statement singled out Parliamentary Secretary to the Prime Minister, Josh Frydenberg, giving him a big pat on the back for his work to date on the Repeal Day legislation.

“We will be encouraging the Government to revisit legislative amendments like the ‘water trigger’, as recommended by the Productivity Commission, to remove roadblocks to further investment in resource projects,” the statement said.

“Industry supports strong environmental standards and a world-class safety regime; two goals that can be achieved without onerous conditions that threaten performance and competitiveness.”